10,314 Shares in Bruker Co. (NASDAQ:BRKR) Bought by New Age Alpha Advisors LLC

New Age Alpha Advisors LLC bought a new stake in shares of Bruker Co. (NASDAQ:BRKR) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,314 shares of the medical research company’s stock, valued at approximately $605,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Norges Bank purchased a new position in shares of Bruker in the 4th quarter valued at approximately $63,378,000. JPMorgan Chase & Co. increased its stake in Bruker by 139.3% during the 4th quarter. JPMorgan Chase & Co. now owns 526,166 shares of the medical research company’s stock valued at $30,844,000 after purchasing an additional 306,282 shares in the last quarter. WINTON GROUP Ltd acquired a new position in Bruker during the 4th quarter valued at approximately $562,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Bruker by 38.6% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 36,628 shares of the medical research company’s stock worth $2,188,000 after buying an additional 10,206 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Bruker during the fourth quarter worth $1,260,000. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on BRKR shares. Barclays reduced their target price on Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a report on Monday, February 24th. Stifel Nicolaus cut their price target on shares of Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a report on Friday, February 14th. The Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective for the company in a research note on Thursday, December 5th. Finally, Bank of America increased their price objective on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $70.50.

Bruker Trading Down 0.8 %

BRKR stock opened at $41.74 on Tuesday. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. Bruker Co. has a 52-week low of $40.60 and a 52-week high of $94.35. The company’s 50-day simple moving average is $50.24 and its 200-day simple moving average is $56.75. The firm has a market cap of $6.33 billion, a P/E ratio of 54.92, a PEG ratio of 2.16 and a beta of 1.18.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. As a group, equities analysts forecast that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 17th were paid a dividend of $0.05 per share. The ex-dividend date was Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.48%. Bruker’s dividend payout ratio is currently 26.32%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.